Efficacy of Hypnotic Medications and Other Medications Used for Insomnia

Sleep Medicine Clinics

Volumn 1, Issue 3, 2006, Pages 387-397

  Feren, Stephen ^a   Katyal, Anup ^a   Walsh, James K ^a,b  

^a Sleep Medicine and Research Center   (United States)

^b SAINT LOUIS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 60449091288     PISSN: 1556407X     EISSN: 15564088     Source Type: Journal    
DOI: 10.1016/j.jsmc.2006.06.011     Document Type: Review

References (65)

1. Ohayon M. Epidemiology of insomnia: what we know and what we still need to learn. Sleep Med Rev 6 2 (2002) 97-111
2. Walsh J.K., and Engelhardt C.L. The direct economic costs of insomnia in the United States for 1995. Sleep 22 Suppl 2 (1999) S386-S393
3. Stoller M.K. The socio-economics of insomnia: the materials and the methods. Eur Psychiatry 12 Suppl 1 (1997) 41S-48S
4. Léger D., Massuel M.A., and Metlaine A. Professional correlates of insomnia. Sleep 29 2 (2006) 171-178
5. National Institutes of Health State of the Science Conference Statement on Manifestations and Management of Chronic Insomnia in Adults. Sleep 28 (2005) 1049-1057
6. Kryger M.H., Steljes D., Pouliot Z., et al. Subjective versus objective evaluation of hypnotic efficacy: experience with zolpidem. Sleep 14 5 (1991) 399-407
7. Ohayon M.M. Prevalence of DSM-IV diagnostic criteria of insomnia: distinguishing insomnia related to mental disorders from sleep disorders. J Psychiatr Res 31 3 (1997) 333-346
8. Nowell P.D., Mazumdar S., Buysse D.J., et al. Benzodiazepines and zolpidem for chronic insomnia: a meta-analysis of treatment efficacy. JAMA 278 (1997) 2170-2177
9. Holbrook A.M., Crowther R., Lotter A., et al. Meta-analysis of benzodiazepine use in the treatment of insomnia. Can Med Assoc J 162 2 (2000) 225-233
10. Walsh J.K., Pollak C.P., Scharf M.B., et al. Lack of residual sedation following middle-of-the-night zaleplon administration in sleep maintenance insomnia. Clin Neuropharmacol 23 1 (2000) 17-21
11. Oswald I., French C., Adam K., et al. Benzodiazepine hypnotics remain effective for 24 weeks. Br Med J (Clin Res Ed) 284 6319 (1982) 860-863
12. Scharf M.B., Roth T., Vogel G.W., et al. A multicenter, placebo-controlled study evaluating zolpidem in the treatment of chronic insomnia. J Clin Psychiatry 55 (1994) 192-199
13. Walsh J.K., Vogel G.W., Scharf M., et al. A five week, polysomnographic assessment of zaleplon 10 mg for the treatment of primary insomnia. Sleep Med 1 (2000) 41-49
14. Krystal A.D., Walsh J.K., Laska E., et al. Sustained efficacy of eszopiclone over 6 months of nightly treatment: results of a randomized, double-blind, placebo-controlled study in adults with chronic insomnia. Sleep 26 (2003) 793-799
15. Roth T., Walsh J.K., Krystal A., et al. An evaluation of the efficacy and safety of eszopiclone over 12 months in patients with chronic primary insomnia. Sleep Med 6 (2005) 487-495
16. Winkelman J., and Pies R. Current patterns and future directions in the treatment of insomnia. Ann Clin Psychiatry 17 1 (2005) 31-40
17. Walsh J.K., Roth T., Randazzo A.C., et al. Eight weeks of non-nightly use of zolpidem for primary insomnia. Sleep 23 8 (2000) 1087-1096
18. Perlis M., McCall W.V., Krystal A., et al. Long-term, non-nightly administration of zolpidem in the treatment of patients with primary insomnia. J Clin Psychiatry 65 (2004) 1128-1137
19. Ohayon M.M., Caulet M., Arbus L., et al. Are prescribed medications effective in the treatment of insomnia complaints?. J Psychosom Res 47 (1999) 359-368
20. Balter M.B., and Uhlenhuth E.H. The beneficial and adverse effects of hypnotics. J Clin Psychiatry 52 7 Suppl (1991) 16-23
21. Dorsey C.M., Lee K.A., and Scharf M.B. Effect of zolpidem on sleep in women with perimenopausal and postmenopausal insomnia: a 4-week, randomized, multicenter, double-blind, placebo-controlled study. Clin Ther 26 10 (2004) 1578-1586
22. Asnis G.M., Chakraburtty A., DuBoff E.A., et al. Zolpidem for persistent insomnia in SSRI-treated depressed patients. J Clin Psychiatry 60 10 (1999) 668-676
23. Fava M., McCall W.V., Krystal A., et al. Eszopiclone co-administered with fluoxetine in patients with insomnia coexisting with major depressive disorder. Biol Psychiatry 59 11 (2006) 1052-1060
24. Brzezinski A. Melatonin in humans. N Engl J Med 336 3 (1997) 186-195
25. Kato K., Hirai K., Nishiyama K., et al. Neurochemical properties of ramelteon (TAK-375), a selective MT1/MT2 receptor agonist. Neuropharmacology 48 2 (2005) 301-310
26. Ekmekcioglu C. Melatonin receptors in humans: biological role and clinical relevance. Biomed Pharmacother 60 3 (2006) 97-108
27. Griffiths R.R., and Johnson M.W. Relative abuse liability of hypnotic drugs: a conceptual framework and algorithm for differentiating among compounds. J Clin Psychiatry 66 Suppl 9 (2005) 31-41
28. Roth T., Stubbs C., and Walsh J.K. Ramelteon (TAK-375), a selective MT1/MT2-receptor agonist, reduces latency to persistent sleep in a model of transient insomnia related to a novel sleep environment. Sleep 28 (2005) 303-307
29. Erman M., Seiden D., Zammit G., et al. An efficacy, safety, and dose-response study of ramelteon in patients with chronic primary insomnia. Sleep Med 7 (2006) 17-24
30. Roth T, Seiden D, Weigand S, et al. Phase III study to determine the efficacy of ramelteon in elderly patients with chronic insomnia [abstract no. II-87]. Presented at the 45th annual meeting of the New Clinical Drug Evaluation Unit (NCDEU). Boca Raton (FL), June 6-9, 2005.
31. Zammit G., Roth T., Erman M., et al. Double-blind, placebo-controlled polysomnography and outpatient trial to evaluate the efficacy and safety of ramelteon in adult patients with chronic insomnia. [abstract]. Sleep 28 (2005) A228
32. Roth T., Seiden D., Sainati S., et al. Effects of ramelteon on patient-reported sleep latency in older adults with chronic insomnia. Sleep Med 7 4 (2006) 312-318
33. Almeida Montes L.G., Ontiveros Uribe M.P., Cortes Sotres J., et al. Treatment of primary insomnia with melatonin: a double-blind, placebo-controlled, crossover study. J Psychiatry Neurosci 28 3 (2003) 191-196
34. James S.P., Sack D.A., Rosenthal N.E., et al. Melatonin administration in insomnia. Neuropsychopharmacology 3 1 (1990) 19-23
35. Ellis C.M., Lemmens G., and Parkes J.D. Melatonin and insomnia. J Sleep Res 5 1 (1996) 61-65
36. Zhdanova I.V., Wurtman R.J., Regan M.M., et al. Melatonin treatment for age-related insomnia. J Clin Endocrinol Metab 86 10 (2001) 4727-4730
37. MacFarlane J.G., Cleghorn J.M., Brown G.M., et al. The effects of exogenous melatonin on the total sleep time and daytime alertness of chronic insomniacs: a preliminary study. Biol Psychiatry 30 4 (1991) 371-376
38. Haimov I., Lavie P., Laudon M., et al. Melatonin replacement therapy of elderly insomniacs. Sleep 18 7 (1995) 598-603
39. McCall W.V., D'Agostino Jr. R., and Dunn A. A meta-analysis of sleep changes associated with placebo in hypnotic clinical trials. Sleep Med 4 1 (2003) 57-62
40. Garfinkel D., Laudon M., and Zisapel N. Improvement of sleep quality by controlled-release melatonin in benzodiazepine-treated elderly insomniacs. Arch Gerontol Geriatr 24 2 (1997) 223-231
41. Walsh J.K. Drugs used to treat insomnia in 2002: regulatory-based rather than evidence-based medicine. Sleep 27 (2004) 1441-1442
42. Mendelson W.B. A review of the evidence for the efficacy and safety of trazodone in insomnia. J Clin Psychiatry 66 4 (2005) 469-476
43. Montgomery I., Oswald I., Morgan K., et al. Trazodone enhances sleep in subjective quality but not in objective duration. Br J Clin Pharmacol 16 2 (1983) 139-144
44. Walsh J.K., Erman M., Erwin C.W., et al. Subjective hypnotic efficacy of trazodone and zolpidem in DSM-III-R primary insomnia. Hum Psychopharmacol 13 (1998) 191-198
45. Haffmans P.M., and Vos M.S. The effects of trazodone on sleep disturbances induced by brofaromine. Eur Psychiatry 14 3 (1999) 167-171
46. Nierenberg A.A., Adler L.A., Peselow E., et al. Trazodone for antidepressant-associated insomnia. Am J Psychiatry 151 (1994) 1069-1072
47. Auron Zaltzman D. [Amitriptyline hydrochloride in the treatment of anxiety and insomnia and as a tranquilizer]. Neurol Neurocir Psiquiatr 17 3 (1976) 165-169 [in Spanish]
48. Brasseur R. [Double-blind comparison between amitriptyline Diffucaps and ordinary amitriptyline in sleep disorders of depressive origin]. Acta Psychiatr Belg 75 2 (1975) 182-189 [in Spanish]
49. Diaz Solano C. [Amitriptyline in the treatment of anxiety and insomnia anal as a tranquilizer]. Neurol Neurocir Psiquiatr 17 3 (1976) 133-138 [in Spanish]
50. Srisurapanont M., and Jarusuraisin N. Amitriptyline vs. lorazepam in the treatment of opiate-withdrawal insomnia: a randomized double-blind study. Acta Psychiatr Scand 97 3 (1998) 233-235
51. Hajak G., Rodenbeck A., Voderholzer U., et al. Doxepin in the treatment of primary insomnia: a placebo-controlled, double-blind, polysomnographic study. J Clin Psychiatry 62 6 (2001) 453-463
52. Hajak G., Rodenbeck A., Adler L., et al. Nocturnal melatonin secretion and sleep after doxepin administration in chronic primary insomnia. Pharmacopsychiatry 29 5 (1996) 187-192
53. Rodenbeck A., Cohrs S., Jordan W., et al. The sleep-improving effects of doxepin are paralleled by a normalized plasma cortisol secretion in primary insomnia. A placebo-controlled, double-blind, randomized, cross-over study followed by an open treatment over 3 weeks. Psychopharmacology (Berl) 170 4 (2003) 423-428
54. Roth T., Zorick F., Wittig R., et al. The effects of doxepin HCl on sleep and depression. J Clin Psychiatry 43 9 (1982) 366-368
55. Sorensen M., Jorgensen J., Viby-Mogensen J., et al. Double-blind group comparative study using the new anti-depressant Org 3770, placebo and diazepam in patients with expected insomnia and anxiety before elective gynaecological surgery. Acta Psychiatr Scand 71 4 (1985) 339-346
56. Winokur A., Sateia M.J., Hayes J.B., et al. Acute effects of mirtazapine on sleep continuity and sleep architecture in depressed patients: a pilot study. Biol Psychiatry 48 1 (2000) 75-78
57. Radhakishun F.S., van den Bos J., van der Heijden B.C., et al. Mirtazapine effects on alertness and sleep in patients as recorded by interactive telecommunication during treatment with different dosing regimens. J Clin Psychopharmacol 20 5 (2000) 531-537
58. Shen J., Chung S.A., Kayumov L., et al. Polysomnographic and symptomatological analyses of major depressive disorder patients treated with mirtazapine. Can J Psychiatry 51 1 (2006) 27-34
59. Winokur A., DeMartinis N.A., McNally D.P., et al. Comparative effects of mirtazepine and fluoxetine on sleep physiology measures in patients with major depression and insomnia. J Clin Psychiatry 64 (2003) 1224-1229
60. 2C receptors in vivo. Biol Psychiatry 47 (2000) 468-470
61. Salin-Pascual R.J., Herrera-Estrella M., Galicia-Polo L., et al. Olanzapine acute administration in schizophrenic patients increases delta sleep and sleep efficiency. Biol Psychiatry 46 1 (1999) 141-143
62. Walsh J.K., Perlis M., Rosenthal M., et al. Tiagabine increases slow wave sleep in a dose-dependent fashion, without affecting traditional efficacy measures, in adults with primary insomnia. J Clin Sleep Med 2 (2006) 35-41
63. Roth T., Wright K.P., and Walsh J.K. Effect of tiagabine on sleep in elderly subjects with primary insomnia: a randomized, double-blind, placebo-controlled study. Sleep 29 (2006) 335-341
64. Walsh J.K., Zammit G., Schweitzer P.K., et al. Tiagabine enhances slow wave sleep and sleep maintenance in primary insomnia. Sleep Med 7 (2006) 155-161
65. Buscemi N., Vandermeer B., Friesen C., et al. Manifestations and management of chronic insomnia in adults. Evidence report/technology assessment no. 125. (University of Alberta Evidence-based Practice Center). Agency for Healthcare Research and Quality Publication # 05-E021-2 (2005), Agency for Healthcare Research and Quality, Rockville (MD)